Soligenix Announces Further Progress With ThermoVaxT For Long-Term Vaccine ThermoStability ($SNGX)

Soligenix Announces Further Progress With ThermoVaxT For Long-Term Vaccine ThermoStability ($SNGX)

Soligenix, Inc. (OTCBB: SNGX) is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestional diseases, and vaccines for certain bioterrorism agents.  Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccine/biodefense segment to develop vaccines and therapeutics for military and civilian applications.

Soligenix announced further progress in the development of ThermoVax™.  ThermoVax™is a vaccine thermostabilization technology that could prove effective in keeping vaccines viable during extreme temperatures.  Prototype vaccines kept at elevated temperatures for more than three months have demonstrated stability and effectiveness after exposure to environmental stress conditions.

Robert N. Brey, PhD, Chief Scientific Officer of Soligenix, commented,

"We continue to be pleased with the data generated thus far with ThermoVax™.  The ability of vaccines to withstand extreme temperatures is a significant step forward in vaccine technology. ThermoVax™ may also enable preparation of otherwise difficult multivalent (protective against multiple pathogens) formulations. We plan to apply ThermoVax™ to other conventional vaccines that require refrigeration."

Read the full article here.